Eloxx Pharmaceuticals, Inc. (ELOX) Social Stream



Eloxx Pharmaceuticals, Inc. (ELOX): $1.35

-0.02 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About ELOX

$ELOX @sdotmouse no huge dump, no offering, just people exiting for a little bit after the announcement that phase 2 results would be released in Q4. Good work on your short, you clearly were on the right end of the recent PR. The science is solid here though, won’t be a penny stock forever.
TradeNash, published July 8, 2021

What Else are ELOX Traders Talking About?


Other tickers frequently mentioned alongside ELOX is VRTX.

Other Notable StockTweets About ELOX


Today's Top Pull Back Play with over 2M Volume Watching these for a potential bounce up this week.

16m volume $mmat -19.33%
2.4m volume $cbli -18.91%
9.2m volume $pbts -18.36%
4.2m volume $elox -17.10%
2m volume $rcat -16.91%

Currently up 235% YTD. Check out our super friendly and FREE community, filled with educational content, helpful pro traders and live alerts. (information/link in my profile bio)

ArcAceTrade, published July 7, 2021

$ELOX Mizuho Securities Starts Eloxx Pharma (ELOX) at Buy

June 29, 2021 4:06 PM
Mizuho Securities analyst Defei Yang initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $3.10.

The analyst comments "Eloxx Pharmaceuticals is developing novel therapies for nonsense mutations, which are present in ~10% of patients across multiple rare disease settings. Following in the footsteps of $VRTX Pharma (not covered), the company's lead program; ELX-02 is in cystic fibrosis patients with nonsense mutations, where the standard of care is currently limited. Clinical data from an ongoing Phase II study is expected in 2H21 and is likely to be a major catalyst for the company. We highlight the bar for success in this report, along with important pre-clinical data from ELX-02 in highly relevant models of CF."

JodyDurham, published June 29, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6309 seconds.